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Aminoacidopathies are a group of rare and diverse disorders, caused by the deficiency of an enzyme or transporter
involved in amino acid metabolism. For most aminoacidopathies, dietary management is the mainstay of treatment.
Such treatment includes severe natural protein restriction, combined with protein substitution with all amino acids
except the amino acids prior to the metabolic block and enriched with the amino acid that has become essential
by the enzymatic defect. For some aminoacidopathies, supplementation of one or two amino acids, that have not
become essential by the enzymatic defect, has been suggested. This so-called single amino acid supplementation
can serve different treatment objectives, but evidence is limited. The aim of the present article is to provide a
systematic review on the reasons for applications of single amino acid supplementation in aminoacidopathies
treated with natural protein restriction and synthetic amino acid mixtures.
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Inborn errors of amino acid metabolism or aminoacidopa-
thies are a group of rare and diverse disorders, in total af-
fecting about 1 in 1000 humans worldwide [1]. These
disorders can be subdivided in organic acidurias, urea
cycle defects, transport defects of urea cycle intermediates,
and remaining aminoacidopathies. Clinical phenotypes are
highly variable, ranging from asymptomatic to life-
threatening metabolic decompensation already at neo-
natal age, encompassing slow deterioration of mental
capacities at later age [1].
At present, dietary management is the mainstay of treat-
ment for most aminoacidopathies. Dietary treatment aims
to prevent accumulation of the substrates and associated
metabolites to toxic levels, and to restore deficiencies of
the enzymatic products [2]. This can be accomplished by
natural protein restriction, combined with protein substi-
tution with all amino acids except for the amino acids
prior to the metabolic block and enriched with the amino* Correspondence: f.j.van.spronsen@umcg.nl
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stated.acid that has become essential by the enzymatic defect
[3,4]. Also, additional supplementation of one or two sin-
gle amino acids may be required for other purposes.
This so-called single amino acid (SAA) supplementation
is especially important to overcome a deficiency of the
amino acid that has become essential due to the enzymatic
defect. Clinically, deficiencies of specific amino acids may
result in skin (hair and nail) problems, poor growth, and
developmental delay [5-7]. Biochemically, such deficien-
cies might be detected by studying amino acid concentra-
tions in plasma. An alternative strategy to detect amino
acid deficiencies is the indicator amino acid oxidation
method [8], but this method should be used for research
purposes rather than for clinical practice.
The main objective of this article is to present a system-
atic review on SAA supplementation in aminoacidopa-
thies. We focus on objectives other than to overcome a
deficiency of the amino acid that has become essential by
the enzymatic defect. Such treatment objectives include:
A. Prevention of a deficiency of a specific amino acid
that has not become essential by the enzymatic
defect.l Ltd. This is an Open Access article distributed under the terms of the Creative
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substrates prior to the metabolic block, either by
reducing synthesis or increasing excretion.
C. Competition with toxic agents for entry into target
organs, especially the brain.
To our best knowledge, we identified all aminoacidopa-
thies treated with natural protein restriction and synthetic
amino acid mixtures for which additional SAA supple-
mentation has been reported. The rationale underlying the
treatment strategies and reported results were determined,
while taking into account the levels of evidence.
Methods
Search strategy
We conducted a literature search on PubMed and
EMBASE without date limits up to 30th of October, 2012.
In PubMed, the Medical Subject Headings (MesH) terms
used included (“Amino Acids/therapeutic use”[Mesh])
AND ("Amino Acid Metabolism, Inborn Errors"[Mesh]
OR "Amino Acid Transport Disorders, Inborn"[Mesh] OR
"Metabolism, Inborn Errors"[Mesh:NoExp]). In EMBASE,
EMTREE tools used included ('amino acid'/exp/dd_dt,
dd_ad,dd_ct) AND (('disorders of amino acid and protein
metabolism'/exp) OR ('inborn error of metabolism'/de).
The search term subheadings dd_dt, dd_ad, and dd_ct
refer to drug therapy, administration and dosage, and clin-
ical trial respectively. Additional searches were performed
on 10th of June 2013 to identify possible newly added arti-
cles (published in 2012 or 2013 only) that were not yet
indexed for either MesH terms or EMTREE tools. In these
additional searches, (isovaleric acidemia AND glycine),
(methylmalonic acidemia AND (isoleucine OR valine)),
(“propionic acidemia” AND (isoleucine OR valine OR gly-
cine)), (glutaric aciduria type 1 AND (arginine OR homo-
arginine OR ornithine)), (maple syrup urine disease AND
(isoleucine OR valine OR norleucine)), (phenylketonuria
AND (tryptophan OR threonine OR glutamine OR glu-
tamate OR asparagine)), (tyrosinemia type 1 AND phenyl-
alanine), ((“gyrate atrophy” OR “ornithine aminotransferase
deficiency”) AND (lysine OR proline)), (guanidinoacetate
methyltransferase deficiency AND ornithine), and (homo-
cystinuria AND (cysteine OR cystine OR arginine)) were
entered as free text for both databases. Language limits for
all searches were set at English and German.
Study selection
First, titles and/or abstracts of all identified non-duplicate
references were screened to select eligible studies. Eligibil-
ity criteria included: 1) involving an aminoacidopathy
which is treated (among else) with natural protein restric-
tion and a synthetic amino acid mixture; 2) possibly refer-
ring to SAA supplementation. Then, full-text articles of the
selected references were retrieved and read independentlyto assess whether the inclusion criteria were met. Inclu-
sion criteria were: 1) SAA treatment regimens are clearly
defined; 2) SAA treatment effects are clearly defined. Arti-
cles only addressing the application of SAA supplementa-
tion to restore the concentrations of the amino acid that
has become essential by the enzymatic defect were ex-
cluded, as were abstracts and conference proceedings, and
research performed in animal models that are not based
on a genetic defect. The reference lists of all full-read arti-
cles were reviewed to identify additional eligible studies.
Results of the reviewing process are outlined in Figure 1.Results
Table 1 presents an overview of all relevant aminoacidopa-
thies for which SAA supplementation has been described,
including the treatment strategy and the level of evidence.
This table includes only the aminoacidopathies for which
severe natural protein restriction and an amino acid mix-
ture devoid of the offending precursor amino acids or an
essential amino acid supplement is a generally accepted
treatment. More detailed information about the results of
SAA supplementation in these aminoacidopathies can be
found in Additional file 1. In addition, three aminoacido-
pathies (hyperammonaemia-hyperornithinaemia-homoci-
trullinuria syndrome, lysinuric protein intolerance, and
nonketotic hyperglycinemia), for which combined natural
protein restriction and an essential amino acid mixture is
more controversial, are worth discussion with respect to
SAA supplementation. We will now continue by address-
ing these SAA supplementation regimens for each ami-
noacidopathy individually.Isovaleric acidemia
Isovaleric acidemia (McKusick 243500) is an inherited de-
fect of leucine catabolism, caused by isovaleryl-CoA de-
hydrogenase deficiency. This deficiency results in the
accumulation of isovaleryl-CoA and its metabolites, in-
cluding isovaleric acid (IVA). Under stable conditions, de-
toxification proceeds by alternate pathways in glycine- and
carnitine conjugates, including N-isovalerylglycine (IVG),
which can be easily excreted by the kidneys. However,
after protein intake and/or periods of catabolism [9], cap-
acity of this alternative pathway detoxification does not
suffice. This results in ketoacidosis or, sometimes, even in
coma.
In the case of glycine supplementation treatment,
leucine-loading tests showed higher urinary excretion of
IVG [10-12] and related metabolites [11,12], less increased
plasma IVA concentrations [10,11,13], and no vomiting
[10]. In the case of acute metabolic decompensation, often
precipitated by illness, glycine supplementation has been
described to result in a decline of plasma IVA concentra-
tions, concomitant with an increase in urinary IVG
Figure 1 Flow-chart of the reviewing process.
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logical response after one to two weeks of treatment
[14,15].
As episodes of metabolic decompensation are difficult to
predict, chronic management with glycine to prevent such
episodes has been investigated [16-20]. Several studies sup-
port lower doses for maintenance treatment than for acute
management, in order to prevent side-effects due to hyper-
glycinemia [16-18]. At oral dosages of 300 mg/kg/d, plasma
glycine concentrations up to 1680 μM have been observed,
concomitant with increased lethargy and ataxia [17,18]. In
contrast, Naglak et. al. (1988) did not report on any en-
cephalopathic side-effects of glycine dosed at 600 mg/kg
under constant leucine restriction, although plasma glycine
concentrations at this dosage even reached 2547 ± 591 μM
[16]. Alternatively, to circumvent possible encephalopathic
side-effects or to increase treatment effectiveness, carnitine
administration has been proposed either as monotherapy
or in addition to glycine supplementation [12,17-20]. How-
ever, considering the scope of the present review, evidence
on carnitine supplementation in isovaleric acidemia is not
discussed in further detail. To conclude, glycine supple-
mentation has been shown to be effective both in acute
and chronic management of individual IVA patients (level4–5), but encephalopathic side-effects have been reported
at plasma glycine concentrations > 1000 μM.
Methylmalonic acidemia
Methylmalonic acidemia (MMA; McKusick 251000) is
caused by methylmalonyl-CoA mutase deficiency. To re-
duce accumulation of methylmalonyl–CoA and associ-
ated metabolites, dietary restriction of precursor amino
acids (valine, isoleucine, methionine, and threonine) and
sometimes also odd-chain fatty acids is used. In addition,
fasting should be avoided to prevent endogenous catab-
olism. Under this treatment regimen, some patients suf-
fered from severe acrodermatitis enteropathica like skin
lesions (despite adequate blood zinc concentrations)
which, in some cases, even culminated in sepsis and
death [21]. Especially isoleucine deficiency has been
associated with these skin lesions [6,22-24]. In MMA
patients on dietary treatment, isoleucine and valine defi-
ciencies are regularly observed [25].
SAA supplementation with isoleucine (48–340 mg/d)
and valine (68–170 mg/d) to prevent essential amino
acid deficiencies and associated skin lesions has become
routine clinical practice in some centers without any re-
ported adverse effects [26]. Still, defining optimal dietary
Table 1 Suggested applications of SAA supplements in different aminoacidopathies
Disorder Treatment objective Level of evidence
A B C
IVA Glycine 4-5
MMA Isoleucine + Valine 5
PA Glycine 5
Isoleucine + Valine 5
GA-I Arginine 3b animal
Homoarginine - animal
Ornithine - animal
MSUD Isoleucine + Valine -
Norleucine - animal












OAT deficiency Lysine 4
Proline 4
GAMT deficiency Ornithine Ornithine 5
HCU Arginine 5
Cysteine -
Arginine* Arginine* Arginine* 1b
Therapeutic objective A) correction of amino acid deficiency; B) prevention of toxic accumulation of specific substrates prior to the metabolic block;
C) competition with toxic agents for entry into target organs.
MAIB: N-methyl-aminoisobutyrate; AIB: 2-aminoisobutyrate; NB: 2-aminonorbornane
*Treatment objective is unclear.
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that not only metabolic crises still occur if offending pre-
cursor amino acids are elevated due to endogenous ca-
tabolism, but offending precursor amino acids can
become overly restricted as well. To conclude, additional
isoleucine and valine supplementation to prevent defi-
ciencies in MMA patients has become routine clinical
practice in some centers. Currently, the level of evidence
is 5. So far, its effects and possible side-effects have not
been investigated.
Propionic acidemia
Propionic acidemia (PA; McKusick 232000) is character-
ized by propionyl-CoA carboxylase deficiency, blocking
the BCAA catabolic pathway one step earlier than inMMA. Dietary treatment is very similar to that used in
MMA, with restriction of natural protein and sometimes
also odd-chain fatty acids, as well as supplementation of
a synthetic amino acid mixture devoid of valine, isoleu-
cine, methionine, and threonine being reported. In
addition, fasting should be avoided. In the past, it has
been incorrectly assumed that leucine should be re-
stricted as well, leading to growth restriction without
any benefit on PA symptomatology [28].
As in other inborn errors of amino acid metabolism,
various SAA supplementation treatment strategies have
been proposed. The most widely suggested one is the
use of isoleucine and valine supplementation, compar-
able with the application described for MMA [29]. As in
MMA, deficiencies of both isoleucine and valine are
van Vliet et al. Orphanet Journal of Rare Diseases 2014, 9:7 Page 5 of 14
http://www.ojrd.com/content/9/1/7often observed [25,30]. In addition, Scholl-Bürgi et al.
showed that blood isoleucine and valine concentrations,
in contrast to almost all other amino acids, did not cor-
relate with age [31]. To prevent a relative isoleucine defi-
ciency, the use of routine isoleucine supplementation
(100 mg/d) has been reported [32].
A different SAA treatment includes supplementation
of glycine to promote conjugation of propionyl CoA and
tiglyl CoA, and thereby to stimulate urinary excretion.
This may seem contra intuitive, as hyperglycinaemia is
observed in nearly all PA patients [30]. Blood glycine
concentrations in PA patients, however, have been found
to correlate with blood bicarbonate concentrations [33].
Furthermore, the affinity of propionate to conjugate with
either glycine or carnitine has been hypothesized to be
pH-sensitive, glycine being favoured during periods of
ketoacidosis. Although urinary excretion of propionyl-
glycine and tiglylglycine indeed increased on glycine
supplementation (two doses of 200 mg/kg), this was
complicated by arterial hyperammonemia [34]. It was
therefore concluded that glycine supplementation was
not desirable for PA management. However, it could well
be that the arterial hyperammonemia was due to the in-
creased nitrogen load rather than the glycine supple-
mentation itself, as protein intake had been restricted
earlier to 0.9 g/kg/day for 1.0 g/kg/day was not tolerated.
To conclude, the effect of isoleucine and valine supple-
mentation in PA management has not been investigated,
although preventive isoleucine supplementation is cur-
rently applied in some centers (level 5). Glycine supple-
mentation clearly was not effective (level 5).
Glutaric aciduria type I
Glutaric aciduria type I (GA-I; McKusick 231670) is
caused by glutaryl-CoA dehydrogenase deficiency, which
is required for lysine and tryptophan oxidation. Especially,
elevated brain concentrations of glutaric acid, due to in-
creased cerebral lysine catabolism, correlate with GA-I
symptomatology: acute encephalopathic crises, often typ-
ically precipitated by mild infections. Current manage-
ment includes a protein restricted diet with a lysine-free
and low-tryptophan amino acid mixture, and carnitine ad-
ministration [35].
To reduce brain lysine concentrations even further
without inducing non-brain lysine deficiencies, supple-
mentation of substrates competing with lysine for brain
uptake by the y+ transporter has been suggested as an
additional treatment modality [36-38]. Indeed, homoar-
ginine (a homologue of L-arginine, synthesized from ly-
sine) or arginine supplementation in a GA-I mouse
model showed promising results, whereas ornithine sup-
plementation resulted in increased mortality rates, simi-
lar to high-protein diet exposure [39]. Administration of
homoarginine reduced brain lysine and glutaric acidaccumulation, and increased survival in a GA-I mouse
model [40]. In addition, arginine supplementation de-
creased glutaric acid and 3-hydroxyglutaric acid concen-
trations in both brain and liver. As system y+ transport
is only expressed at the BBB, the inhibition of hepatic
metabolite accumulation by arginine supplementation is
possibly mediated by a different transport mechanism.
Reduced lysine concentrations in cerebral and hepatic
mitochondria of GA-I mice receiving arginine supple-
mentation are indicative of the fact that the human
mitochondrial ornithine carrier 1 might be such a medi-
ating transporter [41].
In GA-I patients, administration of an arginine-
fortified amino acid supplement biochemically resulted
in reduced plasma lysine concentrations and urinary 3-
hydroxyglutarate excretion, compared to historical data
on GA-I patients receiving conventional lysine restricted
dietary regimens. This was accompanied by reduced cal-
culated brain lysine, and increased calculated brain ar-
ginine influx. However, arginine fortification did not
improve growth [42]. In patients receiving either one of
two amino acid supplements, fortified with different
amounts of arginine, no significant correlations were
found between arginine intake and plasma lysine-to-
arginine ratios or neurological outcome [43].
Recommendations for arginine fortification in both
chronic and outpatient sick-day management have been
established based on aforementioned studies. In chronic
management, dietary intake of lysine and arginine of
65–85 mg/kg/day and 100–150 mg/kg/day are suggested,
aiming at a ratio of dietary lysine/arginine intake of 0.5-
0.8. For outpatient sick-day management, recommended
dietary lysine intake is even lower (30–35 mg/kg/day),
whereas recommended dietary arginine intake is even
higher aiming at a dietary lysine/arginine intake of 0.15-
0.20 (mg:mg) [42]. To conclude, homoarginine and argin-
ine supplementation decreased brain lysine and glutaric
acid concentrations in a GA-I mouse model. In patients,
arginine fortification showed reduced calculated brain
lysine (level 3b), but no clinical improvement (level 3b),
and the effect on actual brain lysine and glutaric acid con-
centrations still needs to be investigated.
Maple syrup urine disease
Maple syrup urine disease (MSUD; McKusick 231670) is
an inherited defect in BCAA catabolism caused by defi-
cient branched-chain α-ketoacid dehydrogenase. Although
all BCAA accumulate, leucine accumulation is considered
to be particularly toxic and associated with cerebral mani-
festations. Episodes of metabolic decompensation mainly
occur by endogenous protein catabolism, as observed in
normal postpartum state of neonates or precipitated by
mild infections or physiologic stress in older patients.
Dietary management aims to restrict BCAA intake and to
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amino acid formula was thus designed to contain no
BCAA. However, limited and strongly regulated supple-
mentation of isoleucine and valine has been suggested both
in chronic and acute dietary management [44].
By indicator amino acid oxidation measurement, Riazi
et al. estimated the mean total BCAA requirement for
MSUD patients to be 45 mg/kg/d (leucine 17.3 mg/kg/d;
isoleucine 14.6 mg/kg/d; and valine 13.1 mg/kg/d) [45].
Especially chronic deficiency of isoleucine may result in
acrodermatitis enteropathica-like skin eruptions [46-48].
At present, no acrodermatitis enteropathica-like syn-
dromes have been reported in centers in which supple-
mentation of isoleucine and valine as well as regular
monitoring of blood BCAA concentrations has become
routine clinical practice [44,49].
During episodes of acute metabolic decompensation,
supplementation of isoleucine and valine could serve other
treatment strategies. First, isoleucine and valine may be-
come limited factors for protein synthesis, thereby indu-
cing increased blood leucine concentrations due to
increased proteolysis. To prevent this, supplementation of
isoleucine and valine has been suggested [50,51]. Second,
supplementation of isoleucine and valine has been sug-
gested to compete with leucine for brain uptake and
thereby to counteract the encephalopathic effects of exces-
sive brain leucine accumulation [44]. Such a mechanism
has been shown for the non-physiological amino acid nor-
leucine in an animal model of MSUD [52,53].
Recent management guidelines offer special attention to
isoleucine and valine supplementation in both chronic and
acute management [44,49] and emphasize on regular mon-
itoring of BCAA in blood. In chronic management, supple-
mentation of isoleucine and valine should be targeted at
blood molar ratios of leucine/isoleucine = 2 and leucine/
valine ≥ 0.5 respectively. To maintain these ratios, mean
valine supplementation has been found to decrease during
the first 3 years of life (11.5 mg/kg/d to 5.8 mg/kg/d),
whereas mean isoleucine supplementation remained rela-
tively stable (4.4 mg/kg/d to 5.5 mg/kg/d) [49]. During out-
patient catabolic management, isoleucine and valine
supplementation should be increased to 15–30 mg/kg/d,
whereas inpatient catabolic management should include IV
administration of isoleucine and valine at 20–120 mg/kg/d
[49]. However, IV single valine and isoleucine solutions are
not available in every country for use with MSUD patients.
Research in MSUD patients, rats, and MSUD cell models
showed that, of all BCAA, leucine is most toxic to the
brain [54-56]. Nonetheless, cerebral toxicity from (chronic-
ally) elevated blood isoleucine and/or valine concentrations
cannot be excluded based on the evidence currently
available, and safe upper limits for blood isoleucine and
valine have not yet been established. To conclude, isoleu-
cine and valine supplementation in MSUD patientsresolved dermatitis (level 4–5), but preventive treatment
has not been studied. Moreover, isoleucine and valine
supplementation during acute metabolic decompensation
decreased blood leucine concentrations (level 5), whereas
the effect on brain leucine concentrations still remains to
be investigated.
Phenylketonuria
Phenylketonuria (PKU; McKusick 261600) is caused by de-
ficiency of phenylalanine hydroxylase, resulting in exces-
sively elevated blood phenylalanine concentrations and
normal to slightly decreased blood tyrosine concentrations.
Especially the elevated blood phenylalanine concentrations
have been associated with PKU symptomatology, including
severe mental retardation, developmental delay, seizures,
and psychiatric problems. Dietary management includes
restriction of natural protein and a phenylalanine-free
amino acid supplement. Although early initiation of this
diet has abolished development of severe mental retard-
ation and epilepsy, mild cognitive impairments as well as
neuropsychological deficits still occur. Besides additional
supplementation of tyrosine, different alternative SAA
treatments have been reported. Apart from the very early
but unsuccessful ideas about glutamine supplementation
[57-59], the following suggestions on SAA supplementa-
tion have been proposed.
Threonine supplementation has been suggested to de-
crease blood phenylalanine concentrations. This concept
was based on the observations that blood threonine con-
centrations were inversely related to blood phenylalanine
concentrations in PKU patients [60] and that threonine
administration in rats decreased blood phenylalanine
concentrations exclusively [61]. Indeed, threonine sup-
plementation (50 mg/kg/d; approximately 60% of unsup-
plemented threonine intake) in PKU patients reduced
both blood phenylalanine concentrations as well as urin-
ary phenylalanine excretion [62], possibly due to compe-
tition with phenylalanine for facilitated transport at the
gut-blood barrier [63].
In the 1970s, tryptophan supplementation has been pro-
posed to restore a possible tryptophan deficiency in brain.
The experimental data originate from a rat model treated
with phenylalanine and the phenylalanine hydroxylase in-
hibitor dl-p-chlorophenylalanine [64]. In this pharmaco-
logical model, tryptophan supplementation partly corrected
impairments in the swim maze and of conditioned shock
avoidance as well as decreased brain serotonin and 5-
hydroxyindoleacetic acid concentrations. However, this rat
model is now considered invalid to reflect PKU, as dl-p-
chlorophenylalanine also inhibits tryptophan hydroxylase
[65]. In two late-diagnosed PKU patients, supplementation
of tryptophan (100 mg/kg/d) has been reported to increase
serotonin metabolite concentrations in cerebrospinal fluid
without influencing blood phenylalanine concentrations.
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that showed abnormal vigilance when untreated [66].
Recently, administration of 2-aminoisobutyrate and non-
physiological amino acids such as DL-norleucine, 2-
aminonorbornane, and N-methyl-aminoisobutyrate acting
as inhibitors for various brain amino acid transporters have
been shown to reduce brain phenylalanine concentrations
up to 56% in PKU mice [67]. To conclude, threonine sup-
plementation in PKU patients decreased blood phenylalan-
ine concentrations in a single study (level 3b), while
tryptophan supplementation seemed to have a positive ef-
fect in two late-diagnosed and untreated patients (level 4).
Tyrosinemia type I
Hereditary tyrosinemia type I (HT1; McKusick 276600)
is caused by a deficiency of fumarylacetoacetase. This
enzyme is responsible for the conversion of fumarylace-
toacetate to fumarate and acetoacetate, the last step in
tyrosine catabolism. Untreated, the enzymatic block re-
sults in accumulation of extremely toxic metabolites
(including maleylacetoacetate, fumarylacetoacetate, suc-
cinylacetoacetate, and succinylacetone) causing liver
damage. As a consequence of the liver damage, markedly
elevated blood tyrosine (phenylalanine and methionine)
concentrations occur. The principal treatment is the ad-
ministration of 2-(2-nitro-4-trifluoromethylbenzyl)-1,3-
cyclohexanedione (NTBC) to prevent accumulation of
these toxic tyrosine metabolites by inhibiting tyrosine
catabolism at an earlier step. Additional dietary manage-
ment includes natural protein restriction supplemented
with an amino acid mixture devoid of tyrosine as well as
phenylalanine, as 27-41% of phenylalanine has been
shown to be converted to tyrosine in the first 5–8 hours
after intake [68,69]. Targeting the complications of this
treatment regimen, two different types of single amino
acid supplementation have been described.
Firstly, phenylalanine supplementation has been sug-
gested to restore its potential deficiency [70]. With diet-
ary restriction of both tyrosine and phenylalanine, very
low blood phenylalanine concentrations have been re-
ported [70,71], that may be improved by supplementing
with additional phenylalanine [70]. Concerns have been
raised that phenylalanine deficiency in HT1 would limit
protein synthesis, and thereby impair cognitive outcome
and growth [70,71]. However, no data are available on
the safe lower limits of blood phenylalanine concentra-
tions, which, theoretically, can be an age-dependent par-
ameter, related to maintenance of protein synthesis to
facilitate (brain) development and growth. On the other
hand, phenylalanine supplementation may limit natural
tyrosine tolerance by increased conversion of phenyl-
alanine to tyrosine.
Secondly, in rats, threonine supplementation has been
shown to partly prevent the ocular lesions caused bytyrosine toxicity [72-75]. Although the underlying mech-
anism is still unknown, it has been suggested that blood
tyrosine concentrations decrease if tyrosine administra-
tion is combined with threonine [73,74]. Therefore, it
can be hypothesized that threonine could protect against
ocular lesions by lowering blood tyrosine concentrations
either by competition with tyrosine and/or phenylalanine
for uptake at the gut-blood barrier or in the renal tu-
bules, or by promoting tyrosine oxidation in the liver
[75]. However, as threonine supplementation has also
been shown to partly prevent ocular lesions with NTBC
administration without reducing blood tyrosine concen-
trations, the positive effects of threonine do not seem to
be solely due to a reduction of hypertyrosinemia [75].
To conclude, additional phenylalanine supplementation
in HT1 patients clearly increased the otherwise very low
blood phenylalanine concentrations (level 4), but the
possible clinical effects remain to be investigated. More-
over, threonine supplementation showed positive effects
in hypertyrosinemic rats on ocular lesions, but no clin-
ical studies have been conducted yet.
Ornithine aminotransferase deficiency
Ornithine aminotransferase (OAT) deficiency or gyrate at-
rophy (GA; McKusick 258870) is an inherited deficiency
of ornithine aminotransferase. Using pyridoxal-phosphate
as a cofactor, the enzyme is responsible for the reversible
conversion of ornithine and α-ketoglutarate to pyrroline-
5-carboxylate and glutamate. Clinically, GA is mostly
characterized by a slowly progressive loss of vision, cul-
minating in blindness by the fifth decade of life. However,
a neonatal presentation with acute hyperammonemia is
also recognized [76]. Biochemically, the enzyme deficiency
results in 10–20 times elevated blood ornithine concentra-
tions. Although some patients respond to pyridoxine ad-
ministration, the cornerstone of treatment is an arginine
restricted diet. In practice, this treatment includes restric-
tion of natural protein with supplementation of a synthetic
amino acid mixture devoid of arginine.
Different SAA supplementation regimens have been in-
vestigated for OAT deficiency. Firstly, lysine supplementa-
tion (10–15 g/d) has been shown to decrease blood
ornithine concentrations by increasing its urinary excre-
tion [77,78]. This is probably due to the fact that ornithine
and arginine share a common renal transport system with
lysine and cyst(e)ine. Whether this treatment could slow
or prevent loss of vision, or could increase protein toler-
ance, has not been investigated.
Secondly, proline supplementation has been hypothe-
sized to restore a proline deficiency [79,80]. Ornithine
catabolism is considered important for proline synthesis
especially in the retinal pigment epithelium, where OAT
activity is ten times higher compared to the liver [81].
Moreover, oral ornithine loading in GA patients could
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subjects, suggesting that proline indeed becomes an es-
sential amino acid in GA [80]. In an in vitro model of
human retinal pigment epithelial cells, administration of
proline could prevent the cytotoxic effects of OAT defi-
ciency [82]. In GA patients, proline supplementation
was found to minimize chorioretinal deterioration (in 3
of 4 patients) and even improve vision in 1 patient [79].
To conclude, lysine supplementation in GA patients re-
duced blood ornithine concentrations by increasing its
urinary excretion (level 4), and proline supplementation
seemed to have a positive effect on vision (level 4). How-
ever, further evidence is required.
Guanidinoacetate methyltransferase deficiency
Guanidinoacetate methyltransferase (GAMT; McKusick
601240) deficiency is an inherited disorder of creatine
synthesis. Clinically, untreated GAMT deficiency mainly
results in expressive language impairments, extrapyram-
idal movements, epilepsy, autistic and self-injurious be-
haviour, and developmental delay. Biochemically, the
enzymatic block prevents creatine to be synthesized
from guanidinoacetate (GAA). Hence, the disorder is
characterized by accumulation of GAA and deficiency of
creatine. Treatment includes creatine supplementation
in order to restore cerebral creatine levels [83]. GAA is
considered to be toxic. To prevent accumulation, argin-
ine restriction, administration of sodium benzoate, and
ornithine supplementation have been proposed [84-86].
Arginine (combined with glycine) is the precursor of
GAA. Ornithine may decrease the conversion of arginine
to GAA [85] and reduce tubular arginine reabsorption,
as both amino acids use the same dibasic amino acid
transporter [87], while sodium benzoate removes glycine.
Combined arginine restriction and ornithine supplemen-
tation (100 and 400 mg/kg/d) has been reported to de-
crease blood arginine as well as GAA concentrations
[86,88]. Decreased arginine intake without ornithine
supplementation does not have that effect [84]. Add-
itional ornithine supplementation has been hypothesized
to enhance the GAA lowering effect of dietary arginine
restriction [86]. The exact ornithine dose needed may
probably be between 600 and 800 mg/kg/d [83,89]. To
conclude, ornithine supplementation in combination
with arginine restriction may be helpful in decreasing
blood arginine concentrations in GAMT deficiency pa-
tients (level 5).
Homocystinuria
Homocystinuria (HCU; McKusick 263200) is an inherited
deficiency of cystathionine β-synthase (CBS). Using
pyridoxal-phosphate as a cofactor, the enzyme is involved
in the transsulfuration of homocysteine to form cystathio-
nine. Biochemically, HCU is primarily characterized byincreased blood homocysteine and methionine concentra-
tions. The elevated homocysteine concentrations are asso-
ciated with clinical features, including ectopia lentis,
mental retardation, dental anomalies, osteoporosis, behav-
ioral problems, and arachnodactyly. Some patients re-
spond very well to pyridoxine treatment. If not, dietary
management is indicated including natural protein restric-
tion, an amino acid mixture devoid of methionine, and
supplementation of folate. In addition, different SAA sup-
plementation regimens have been proposed.
In daily practice, cysteine is added to all L-amino acid
supplements (30–50 mg of cysteine per g of protein
equivalent). Besides restoring a deficiency of this amino
acid, cysteine has been hypothesized to reduce blood
homocysteine concentrations. However, to the best of
our knowledge, no study has investigated the possible
homocysteine-lowering effect of cysteine supplementa-
tion in CBS-deficient patients. Four main theories have
been postulated for the possible mechanisms underlying
this effect. As summarized by Kawakami et al., cysteine
may 1) remove homocysteine from its protein-bound
form to a low-molecular weight form, facilitating in-
creased urinary clearance; 2) decrease homocysteine for-
mation from methionine; and 3) increase remethylation
of homocysteine to form methionine [90]. In support of
the first hypothesis, cysteine has been shown to decrease
the percentage of homocysteine bound to protein as well
as the total homocysteine concentration in rats [90].
Both effects were only observed in rats fed a low protein
and low methionine diet [90]. In contrast to the first hy-
pothesis, a fourth hypothesis states that additional cyst-
eine supplementation (in case of total blood cysteine
concentrations <170 μmol/L) may reduce free plasma
homocysteine concentrations [91]. In HCU patients with
blood cystine concentrations <170 μmol/L, the homo-
cysteine free/bound ratio was found to increase, possibly
to maintain the total aminothiol free/bound ratio (thiol
redox) at a constant level. Normally, this thiol redox is
determined by the ratio of free/bound cysteine and is
kept relatively constant [91].
Arginine has been proposed to be supplemented for
two reasons: 1) to decrease endothelial dysfunction [92],
and 2) to compete with renal homocysteine reabsorption
[93]. Although the exact mechanism of vascular damage
in HCU is not well understood, reduced nitrogen oxide
(NO) probably plays a central role and increased con-
centrations of asymmetric dimethylarginine (ADMA), an
endogenous NO synthase inhibitor, have been found. Ar-
ginine supplementation could counteract the effects of
elevated ADMA concentrations [92]. Regarding its sec-
ond treatment objective, arginine glutamate infusion has
been reported to markedly increase urinary homocyst-
eine and homocysteine-cysteine disulphide excretion.
However, blood homocysteine concentrations remained
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ornithine concentrations increased [93]. To conclude, be-
sides the restoration of a cysteine deficiency, cysteine sup-
plementation in HCU patients may have additional effects
that should be investigated. Moreover, arginine supple-
mentation has been found to decrease endothelial dys-





(HHH; McKusick 238970) syndrome is an inherited defect
of the ornithine transporter 1 located on the inner mito-
chondrial membrane. This transporter facilitates ornithine
influx and citrulline efflux. Accordingly, the defect under-
lying HHH syndrome results in cytosolic ornithine accu-
mulation and intramitochondrial ornithine deficiency as
well as citrulline accumulation. Protein restriction is the
main treatment. In some centers, an essential amino acid
mixture, designed for urea cycle disorders, is prescribed
according to clinical tolerance. A variety of SAA supple-
mentation regimens have been investigated, including the
amino acids ornithine, arginine, citrulline, lysine, and pro-
line in HHH syndrome [94-98].
Supplementation with ornithine has been suggested, but
ornithine hydrochloride rather than ornithine supplemen-
tation seems to result in a decrease of blood ammonia
concentrations [94-96], while long-term (exceeding a few
years) or high-dose (inducing blood concentrations ex-
ceeding 600 μmol/L) ornithine has been associated with
retinal toxicity [97].
A study comparing the effects of ornithine, arginine or
citrulline supplementation in two HHH patients suggested
that citrulline is probably the best SAA to supplement for
chronic HHH management [96,98], but a low protein diet
only could be more important for chronic management.
Supplementation of SAA would then be reserved for pe-
riods of metabolic decompensation [96]. Lysine or proline
supplementation has also been proposed for HHH treat-
ment, but the rationale for these hypothesized SAA treat-
ments has not been fully defined. Neither lysine nor
proline has been shown to be beneficial [96]. To conclude,
of all SAA supplementation regimens investigated in
HHH patients, citrulline supplementation was found to be
most effective (level 4), but such supplementation should
probably be reserved for periods of acute metabolic de-
compensation only.
Lysinuric protein intolerance
Lysinuric protein intolerance (LPI; McKusick 222700) is
an inherited defect in the y+LAT1 transporter, involved
in the transport of the dibasic amino acids lysine, argin-
ine, and ornithine in the intestine, kidney, and liver.Most patients develop a strong protein aversion. Inci-
dental protein intake characteristically results in hyper-
ammonemia, caused by a secondary dysfunction of the
urea cycle due to arginine and ornithine deficiency. Add-
itional clinical manifestations include growth retardation,
osteoporosis, hepatosplenomegaly, pulmonary alveolar
proteinosis, renal involvement, and hematological abnor-
malities. Biochemically, LPI is mainly characterized by
markedly increased urinary arginine, ornithine, and lysine
excretion and thereby reduced concentrations of these
amino acids in blood. The mainstay of treatment includes
natural protein restriction to prevent hyperammonemia,
while also providing sufficient essential amino acids to
maintain normal development and growth. To this pur-
pose, sometimes, an essential amino acid mixture is added
as in HHH [99]. Since the first description of LPI in 1965,
different approaches on additional SAA supplementations
have been suggested [100-112].
The most common approach is citrulline supplemen-
tation (0.5-1.1 mmol/kg/d), for which the rationale is to
restore urea cycle functioning [100-102]. Clinically, long-
term citrulline supplementation diminishes protein aver-
sion [101,103,104], increases growth rate [101,103,104],
improves hair quality [103,104], and diminishes centri-
petal obesity as well as folliculitis [103], while the effect
on bone mineral density remains controversial [103,104].
Effects on hepatomegaly and hematological as well as
immunological parameters are not evident [101,104].
Lysine supplementation restores lysine deficiency
[104,108-110], but, unfortunately, long-term lysine supple-
mentation failed to improve growth and to reduce infec-
tion frequency [104,110]. At high dosage (0.8-1.2 g/kg/d),
lysine supplementation even induced gastrointestinal side-
effects as abdominal cramps and diarrhoea [104,108]. Sup-
plementation with homocitrulline to restore the lysine was
unsuccessful [111].
Although arginine and ornithine supplementation were
shown to prevent hyperammonemia [101,102,105,112],
and to stimulate urea formation [101,105], long-term treat-
ment effects remained inconclusive [101,105-107]. Various
studies comparing different (combinations of) SAA sup-
plementation regimens have not provided the optimal
regimen for LPI [100,102,104,107], although all advise
positively on citrulline. To conclude, long-term citrulline
supplementation resulted in clinical improvement of LPI
patients (level 4). The effect of other SAA supplementa-
tion regimens, especially on the long-term, is still unclear.
Nonketotic hyperglycinemia
Nonketotic hyperglycinemia (NKH; McKusick 238300,
238310, and 238330) is characterized by a defective gly-
cine cleavage system, resulting in excessive glycine con-
centrations in both blood and brain. The role of glycine
as an excitatory agonist of the NMDA receptor in the
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brain stem and spinal cord, may well explain NKH symp-
tomatology, which is characterized primarily by intractable
seizures and progressive brain damage. A glycine-
restricted diet has been tried as well as benzoate and
NMDA receptor antagonists, but without any clinical im-
provement, so no effective treatment exists.
To improve outcome, two different SAA supplementa-
tion regimens have been proposed without consistent
positive results, including methionine to prevent toxic
accumulation of glycine by supplying single carbon
groups [113-115] and tryptophan to counteract the ef-
fect of elevated brain glycine on the NMDA receptor
[116,117]. In a single case of NKH, tryptophan supple-
mentation was reported to reduce hyperkinesia, explo-
sive movements, and EEG abnormalities, as well as to
improve verbal functioning and to increase the develop-
mental quotient [116]. However, in another case of
NKH, no behavioural improvements could be demon-
strated on tryptophan supplementation [117]. To con-
clude, methionine supplementation in NKH patients is
probably not effective (level 5), while the reported effects
of tryptophan supplementation are inconsistent (level 5).
Discussion
For most aminoacidopathies, dietary treatment includes
natural protein restriction combined with a synthetic
amino acid mixture devoid of the amino acids prior to
the metabolic block or essential amino acid supplemen-
tation. Especially if the amino acid - that cannot be con-
verted due to the enzymatic defect - is essential (e.g.
phenylalanine in PKU), dietary management has proven
to be effective [49,118,119]. On the contrary, if the non-
convertible amino acid is nonessential (e.g. tyrosine in
Tyrosinemia type I), dietary treatment is less effective
[120,121]. The present review addresses the applications,
objectives, and treatment effects of additional SAA sup-
plementation for purposes other than to overcome a de-
ficiency of the amino acid that has become essential by
the enzymatic defect. Before discussing the main conclu-
sions in further detail, we will first address some meth-
odological issues.
In the present review, supplementation of one or two
amino acids that have become essential by the enzymatic
defect in aminoacidopathies (e.g. tyrosine in PKU, arginine
in urea cycle defects) is not being addressed. Such SAA
supplementation has been widely reported on already.
Supplementation of more than two amino acids is not be-
ing discussed. Various combinations of large neutral
amino acids - except for phenylalanine - have since long
been suggested to serve different biochemical treatment
objectives in PKU, as has already been reviewed by Van
Spronsen et al. [122]. Research on this subject is still being
performed [123], but a study investigating all hypothesizedbiochemical treatment objectives of large neutral amino
acid supplementation in PKU is still hoped-for. More re-
cently, BCAA supplementation for urea cycle defects
treated with alternate pathway treatment (sodium phenyl-
butyrate or phenylacetate/benzoate) has been proposed
[124-126] to prevent strongly decreased blood BCAA con-
centrations [127,128] that have been shown to often
precede metabolic decompensation [129]. Such supple-
mentation is now being used in some clinics, but a benefi-
cial effect has not been demonstrated yet [130]. The
search strategy performed has been limited to articles
written in English and German. Combined with the fact
that especially rather dated articles could not all be ob-
tained, this has posed the possibility of having missed
some relevant articles.
The consideration of SAA supplementation in aminoa-
cidopathies treated with natural protein restriction and
synthetic amino acid mixtures is not always straightfor-
ward. First, treatment is not always based on comparable
strategies. Even for one single aminoacidopathy, different
SAA supplementation regimens can be considered, each
with a different strategy. Also, a specific SAA supplemen-
tation regimen can be hypothesized to serve different
strategies in one single aminoacidopathy. This complicates
the formulation of uniform outcome measures.
Second, the need for SAA supplementation can either
be posed directly by the disorder itself or secondary by its
(dietary) treatment. If required due to dietary treatment,
SAA supplementation mostly aims to restore a deficiency
of specific amino acids. This seems to hold true especially
for isoleucine. Of all amino acids, isoleucine has been
found to be most critical for keratinocyte proliferation
[23]. The importance of monitoring a deficiency of specific
amino acids is exemplified in MMA, where low to very
low concentrations of isoleucine and valine have been
found to be widely present in patients, irrespective of the
natural protein intake [25]. To restore specific amino acid
deficiencies, three different challenges are experienced: 1)
determining the minimal blood concentrations for individ-
ual amino acids; 2) monitoring amino acid levels; and
3) establishing optimal amino acid supplementation
regimens.
The first challenge is especially applicable to HT1, as
no data are available on the safe lower limits of blood
phenylalanine concentrations. Theoretically, this can be
an age-dependent parameter, related to velocity of
(brain) development and growth.
Regarding the second challenge, careful monitoring of
blood amino acid concentrations is crucial to timely de-
tect deficiencies that are not yet clinically detectable,
taking in mind that blood concentrations may not always
reflect processes at a cellular level. Probably the most re-
liable method for detecting an amino acid deficiency is
to determine whether the concentration of the specific
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is very likely), remains stable (indicating that a deficiency
should be considered), or increases (indicating that a de-
ficiency is unlikely) after a meal compared to the over-
night fasting concentration [131]. Interpreting amino
acid status can be particularly challenging if continuous
tube feeding is given. Interpretation is further complicated
by adherence issues. SAA are hard to administer (particu-
larly in very small doses) and no studies address if patients
actually consume them or take them in a way that
utilization will be effective. Of course, an alternative strat-
egy to detect amino acid deficiencies is the indicator
amino acid oxidation method [8], but this method is used
for research purposes rather than for clinical practice.
Regarding the third challenge, optimal treatment in re-
sponse to deficiencies of offending precursor amino
acids still remains to be investigated for most aminoaci-
dopathies. Liberalization of dietary restrictions could
prevent deficiencies of other essential nutrients besides
amino acids, whereas, at the same time, it poses the risk
of metabolic decompensation due to increased concen-
trations of other offending precursor amino acids. On
the other hand, supplementation of SAA raises the ques-
tion whether supplementation should be restricted to
moments of measured deficiency or should be included
in the daily amino acid mixtures.
Third, for many aminoacidopathies, evidence on the
effects of SAA treatment is limited. The rarity of these
disorders probably contributes in part to the fact that
most evidence is restricted to case reports. Also, animal
models, which allow for more invasive measurement and
mechanism-based research, are not available for all dis-
orders. However, even the data obtained from animal
models are only to be used to some degree and, there-
fore, could not fully help us in this review to increase
the level of evidence.
In conclusion, before application in routine clinical
practice can be considered, for most SAA supplementa-
tion treatments in aminoacidopathies, further research is
warranted, both in animal models and patients. It is the
opinion of the authors that clinical research would first
require measuring the need of the SAA to be supple-
mented in individual patients. If results show that for
most patients, having the same disorder, the extra need
of such amino acid is comparable, this could result in in-
clusion of the extra amount in the precursor-free amino
acid mixtures or essential amino acid supplements. The
arginine-enriched amino acid formula for GA-I or the
isoleucine and valine enriched formula for acute MSUD
management, as studied by Strauss et al., may be good
examples [42,49]. To this purpose, well-designed clinical
research is necessary with initially small and later on lar-
ger populations. Multi-center studies, possibly involving
multiple countries, would be crucial in this regard.The first treatment of inherited metabolic diseases was
based on a change in nutritional intake, and this happened
to be the first treatment ever of mental retardation. After
that, many nutritional and medical interventions have been
developed. Now, we might -again- enter a new era in
which rather simple changes in nutritional intake may im-
prove the outcome of patients with such devastating dis-
eases. Such change may be elicited by supplementation of
SAA, including both physiological and non-physiological
amino acids, especially aiming at competition with toxic
agents for entry into target organs (the brain in particular).
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